Incentives and accessibility: A pilot study to promote adherence to tb prophylaxis in a high-risk community

Journal of Urban Health

Volumn 76, Issue 4, 1999, Pages 461-467

  Lorvick, Jennifer ^a   Thompson, Suzanne ^a   Edlin, Brian R ^a   Kral, Alex H ^a   Lifson, Alan R ^a   Watters, John K ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MINNESOTA DEPARTMENT OF HEALTH   (United States)

Author keywords

Adherence; Directly observed preventive therapy; Incentives; Injection drug users; Tuberculosis

Indexed keywords

ISONIAZID; TUBERCULIN;

ARTICLE; COMMUNITY; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROPHYLAXIS; REWARD; SUBCUTANEOUS DRUG ADMINISTRATION; TUBERCULIN TEST; TUBERCULOSIS;

EID: 0032733982     PISSN: 10993460     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02351503     Document Type: Article

References (26)

1. Centers for Disease Control and Prevention. Prevention and control of tuberculosis in US communities with at-risk minorities; and among homeless persons: recommendations of the Advisory Council for the Elimination of Tuberculosis. Morb Mortal Wkly Rep. 1992;41(RR5):l-23.
2. Centers for Disease Control and Prevention. The use of preventive therapy for tuberculosis infection in the United States: recommendations of the Advisory Committee for the Elimination of Tuberculosis. Morb Mortal Wkly Rep. 1990;39(RR-8):9-12.
3. Gourevitch MM, Alcabes P, Wasserman WC, Arno PS. Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis, bit J Tuberc Lung Dis. 1998;2(7):531-540.
4. Daly CL, Hahn HA, Moss AR, Hopewell PC, Schecter GF. Incidence of tuberculosis in injection drug users in San Francisco: impact of anergy. Am J Respir Crit Cam Med. 1998;157:19-22.
5. Snyder DC, Paz EA, Mohle-Boetani J, Black R, Fallstad R, Chin DP. Tuberculosis prevention in methadone maintenance clinics: effectiveness and cost-effectiveness. Am J Respir Crit Care Med. 1999;160:178-185.
6. Smimoff M, Goldberg R, Indyk L, Adler}]. Directly observed therapy in an inner city hospital. Int J Tuberc Lung Dis. 1998;2(2):134-139.
7. Giuffrida A, Torgerson D. Should we pay the patient? Review of financial incentives to enhance patient compliance. BMJ. 1997-315:703-707.
8. Volmink J, Garner P. Systematic review of randomised controlled trials of strategies to promote adherence to tuberculosis treatment. BMJ. 1997;315:1403-1406.
9. Malotte CK, Rhodes F, Mais K. Tuberculosis screening and compliance with return for skin test reading among active drug users. Am J Public Health. 1998;88:792-796.
10. Pilote'L, Tulsky J, Zolopa A, Hahn J, Scheeler G, Moss A. Tuberculosis prophylaxis in the homeless: a trial to improve adherence to referral. Arch Intern Med. 1996;156: 161-165.
11. Malotte CK, Hollingshead JR, Rhodes F. Monetary versus nonmonetary incentives for TB skin test reading among drug users. Am }Prev Med. 1999;16(3):182-188.
12. Watters JK. Trends in risk behavior and HIV seroprevalence among injecting drug users in San Francisco, 1986-1992. J Acquir Immune Defic Syndr. 1994,7:1276-1281.
13. Walters JK, Biernacki P. Targeted sampling: oplions for Ihe sludy of hidden populations. Sac Problems. 1989;36:416-430.
14. Lifson AR, Grant SM, Lorvick J, et al. Two-step tuberculin skin testing of injection drug users recruited from community-based settings. Int J Tuberc Lung Dis. 1997;1: 128-134.
15. Lifson AR, Thompson S, Grant S, Hilk R, Lorvick J. Skin test anergy among injection drug users recruited from communily sellings. J Drug Issues. 1998;28(4):891-904.
16. Cenlers for Disease Conlrol. Purified protein derivative (PPD)-tuberculin anergy and HIV infection: guidelines for anergy testing and management of anergic persons at risk of tuberculosis. Morb Mortal Wkly Rep. 1991;40(RR-5):27-33.
17. Fitzgerald JM, Patrick DM, Strathdee S, et al. Use of incentives to increase compliance for TB screening in a population of intravenous drug users. Vancouver Injection Drug Use Study Group, bit J Tuberc Lung Dis. 1999;3:153-155.
18. Farmer P, Robin S, Ramilus S, Kim JY. Tuberculosis, poverty, and "compliance": lessons from rural Haiti. Semin Respir Infect. 1991;6(4):254-260.
19. Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE. Eleven years of community-based directly observed therapy for tuberculosis. JAMA. 1995;274:945-951.
20. Nazar-Stewarl V, Nolan CM. Results of a dircclly observed inlermittenl isoniazid prevenlive therapy program in a shelter for homeless men. Am Rev Respir Dis. 1992; 146:57-60.
21. Alcabes P, Vossenas P, Cohen R, el al. Compliance with isoniazid in jail. Am Rev Respir Dis. 1989;140:1194-1197.
22. Moriskey DE, Malotte CK, Choi P, et al. A palient education program to improve adherence rates with antituberculosis drug regimens. Health Ed Q. 1990;17(3):253-267.
23. Chaisson RE, Keruly JC, McAvinue S, Gallant JE, Moore RD. Effects of an incentive and education program on return rales for PPD test reading in patienls wilh HIV infection. J Acquir Immune Dis Syndr. 1996;ll:455-459.
24. Mangura BT, Passannante L, Reichman B. An incentive in luberculosis prevenlive Iherapy for an inner city population. Int J Tuberc Lung Dis. 1997;l:576-578.
25. Schecter G. Supervised therapy in San Francisco. Clin Chest Med. 1997;18(1):165-168.
26. El-Sadr W, Medard F, Barlhaud V. Direclly observed therapy for luberculosis: Ihe Harlem Hospital experience, 1993. Am J Public Health. 1996;86(8):1146-1148.